SLC5A2 and hyperuricemia: The key findings of the present study demonstrate that the selective SGLT2 inhibitor, EMPA, improves hemoglobin levels, liver enzymes, serum ferritin, and hyperuricemia in a small-scale clinical observational study involving β-TM patients diagnosed with T2DM.